BRIEF published on 07/08/2026 at 19:16, 1 month 23 days ago GenSight Biologics presents its financial situation and therapeutic advances Treasury GenSight Biologics Phase III RECOVER Early Access GS010/LUMEVOQ®
BRIEF published on 07/08/2026 at 19:16, 1 month 23 days ago GenSight Biologics Announces Cash Position and Business Updates Cash Position Clinical Trials Business Updates Early Access Programs Manufacturing Process
PRESS RELEASE published on 07/08/2026 at 19:11, 1 month 23 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position updates as of June 30, 2026, along with business developments, including proceeds from early access programs and manufacturing process improvements Cash Position Business Updates GenSight Biologics Early Access Programs Manufacturing Process
BRIEF published on 04/28/2026 at 20:40, 4 months 2 days ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
BRIEF published on 04/28/2026 at 20:40, 4 months 2 days ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
PRESS RELEASE published on 04/28/2026 at 20:35, 4 months 2 days ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 19, 2026, in Paris. Shareholders can access preparatory documents online. Meeting details and documents available on company website Annual General Meeting Shareholders Preparatory Documents Meeting Details GenSight Biologics
BRIEF published on 04/07/2026 at 19:04, 4 months 23 days ago GenSight Biologics Reports Cash Status and Early Access Revenues Revenue Cash Position Gene Therapy GenSight Biologics Early Access Program
BRIEF published on 04/07/2026 at 19:04, 4 months 23 days ago GenSight Biologics: Financial Update and Progress on AAC Fundraising Treasury Gene Therapy GenSight Biologics Compassionate Access
PRESS RELEASE published on 04/07/2026 at 18:59, 4 months 23 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 5 months 5 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
Published on 09/01/2026 at 01:39, 8 hours 13 minutes ago GLG Life Tech Corporation Reports 2026 Second Quarter Financial Results
Published on 09/01/2026 at 01:00, 8 hours 52 minutes ago Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
Published on 08/31/2026 at 23:30, 10 hours 22 minutes ago Datametrex Announces Annual and Special Meeting Voting Results
Published on 08/31/2026 at 23:00, 10 hours 52 minutes ago Silver Storm Closes Second and Final Tranche of Non-Brokered Private Placement for Aggregate Gross Proceeds of $21.0 Million
Published on 08/31/2026 at 22:55, 10 hours 57 minutes ago Alset AI Ventures Reports Fiscal Q3 2026 Results, Including $4.1 Million Unrealized, Non-Cash Investment Gain
Published on 09/01/2026 at 09:40, 12 minutes ago KUKA Global Executives Visit Centron for Technical Exchange on Intelligent Assembly Manufacturing
Published on 09/01/2026 at 09:33, 19 minutes ago High-Grade Titanium in Australia: New Exception Drill Results from Surface!
Published on 09/01/2026 at 09:28, 24 minutes ago Back to School, New Kids’ Channels: Fix&Foxi and RiC.today launch in Poland
Published on 09/01/2026 at 09:27, 25 minutes ago XTPL is in the process of securing a strategic investor from Taiwan to strengthen its position in the semiconductor market
Published on 08/31/2026 at 17:45, 16 hours 7 minutes ago Disclosure of transactions in own shares from August 24 to August 28, 2026
Published on 08/31/2026 at 12:00, 21 hours 52 minutes ago Capital increase through exercise of subscription rights
Published on 08/31/2026 at 07:00, 1 day 2 hours ago Biophytis strengthens its financial position and extends its cash runway into Q1 2027
